ARTICLE | Company News
FDA to review Biogen Idec's hemophilia B therapy
March 5, 2013 2:12 AM UTC
Biogen Idec Inc. (NASDAQ:BIIB) said FDA accepted for review a BLA for rFIXFc to treat hemophilia B. Biogen Idec said the application was submitted during 4Q12; a standard review would place the PDUFA ...